CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 91 enrolled
Drug / intervention
VVN461 Ophthalmic Solution 1.0% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06164743
NCT06164743Phase 2Completed
CompareCT.gov

A Phase 2, Double-masked, Randomized, Vehicle-controlled Study of VVN461 Ophthalmic Solution in Treating Post -Operative Ocular Inflammation in Subjects Undergoing Routine Unilateral Cataract Surgery

VivaVision Biotech, Inc·interventional·Posted Dec 11, 2023·Updated Jun 10, 2025

In Brief

A Phase 2 clinical trial evaluating VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, and 1 other intervention for Inflammation. Completed, enrolled 91 participants across 10 sites.

Detailed Summary

This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedDec 11, 2023
Enrollment StartJan 11, 2024
Primary CompletionMay 15, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.6 years ago

Interventions

VVN461 Ophthalmic Solution 1.0%drug

Topical ocular drug

VVN461 Ophthalmic Solution 0.5%drug

Topical ocular drug

Vehicledrug

Topical ocular drug